Table 3 Demographic and clinical information according to ApoE rs429358 genotype of cases and controls in a Chinese sample

Age (years)

47.45 ± 10.04

47.36 ± 9.66

0.939

–

46.15 ± 13.14

46.16 ± 13.27

0.006

0.995

Sex

 Female (%)

19 (26.0)

91 (21.0)

0.337

–

38 (56.7)

210 (59.3)

0.158

0.691

 Male (%)

54(74.0)

342(79.0)

29 (43.3)

144 (40.7)

Years of eudcation

10.21 ± 10.91

8.72 ± 2.60

0.250

–

10.80 ± 11.52

9.14 ± 3.32

-1.164

0.248

Body mass index

23.55 ± 4.12

24.73 ± 3.85

0.034

–

25.00 ± 3.58

25.41 ± 4.20

0.734

0.464

Age of onset (years)

23.34 ± 5.58

22.98 ± 4.77

0.558

–

–

–

–

–

Duration of illness (years)

24.11 ± 9.56

24.53 ± 10.07

0.738

–

–

–

–

–

Mean daily dose (mg/day)

(chlorpromazine equivalents)

411.30 ± 180.56

386.20 ± 167.21

0.312

–

–

–

–

–

PANSS score

 Positive symptoms

12.34 ± 5.19

11.52 ± 4.71

0.175

0.073

–

–

–

–

 Negative symptoms

25.16 ± 8.63

23.45 ± 8.36

0.109

0.097

–

–

–

–

 General psychopathology

26.32 ± 6.09

25.47 ± 5.92

0.264

0.777

–

–

–

–

 Total score

63.82 ± 14.51

60.45 ± 14.39

0.065

0.087

–

–

–

–

 ApoA1 level ( g/L)

1.38 ± 0.40

1.52 ± 0.37

0.010

–

–

–

–

–

 ApoB level ( g/L)

0.86 ± 0.26

0.88 ± 0.26

0.545

–

–

–

–

–

 ApoA1/ApoB

1.71 ± 0.59

1.84 ± 0.64

0.148

–

–

–

–

–